Cart
sales@molnova.com
5-HT1A modulator 2 hydrochloride
CAS No. 3880-76-0
5-HT1A modulator 2 hydrochloride ( —— )
Catalog No. M28119 CAS No. 3880-76-0
5-HT1A modulator 2 hydrochloride is a modulator of 5-HT1A showing an affinity of 53 nM for 5-HT1A binding.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | 32 | Get Quote |
|
| 50MG | 43 | Get Quote |
|
| 100MG | 65 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product Name5-HT1A modulator 2 hydrochloride
-
NoteResearch use only, not for human use.
-
Brief Description5-HT1A modulator 2 hydrochloride is a modulator of 5-HT1A showing an affinity of 53 nM for 5-HT1A binding.
-
Description5-HT1A modulator 2 hydrochloride is a modulator of 5-HT1A showing an affinity of 53 nM for 5-HT1A binding.
-
Synonyms——
-
PathwayEndocrinology/Hormones
-
Target5-HT Receptor
-
RecptorB-Raf;C-Raf;PDGFRβ;FLT3;Kit;PDGFRα
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number3880-76-0
-
Formula Weight213.7
-
Molecular FormulaC11H16ClNO
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCl.COc1cccc2CCC(N)Cc12
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Eric A Murphy, et al. Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRbeta/B-RAF. Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4299-304.
molnova catalog
related products
-
Metoclopramide hydro...
Metoclopramide hydrochloride is a selective dopamine D2 receptor antagonist, used for the treatment of nausea and vomiting.
-
YL0919
An orally active, dual 5-HT1A agonist and selective serotonin reuptake inhibitor with Ki of 0.19 nM and IC50 of 1.78 nM, respectively.
-
cis-Urocanic acid
cis-Urocanic acid is a 5-HT2A receptor agonist (Kd: 4.6 nM). It is an immune modulator that induces immunosuppression by binding to the 5-HT2A receptor.
